UK's Hemogenyx Pharma gains as co takes action to tackle USFDA concerns
10/07/2023 09:41
** Shares of Hemogenyx Pharmaceuticals Plc HEMO.L jump as
much as 16% to 1.695p
** The biopharma group says it has identified source of a
splicing deficiency, which led to USFDA putting group's product
candidate Chimeric Antigen Receptor T-cells on clinical hold,
and has already developed a method to eliminate it
** Co says it received full review letter from USFDA
regarding Investigational New Drug Application for candidate
used for treatment of acute myeloid leukaemia due to a splicing
that occurs during manufacturing process of lentivirus, used to
produce CAR-T cells
** Co, which focuses on developing therapies and treatments
for blood diseases, says lentivirus is being re-manufactured
** Stock currently up 5%, taking YTD gains to about 16%
(Reporting by Aby Jose Koilparambil in Bengaluru)
((abyjose.koilparambil@thomsonreuters.com))